The proteins associated with these neuroprotective effects (HTT, NEFH and NEFL) are potential drug targets for the treatment of obesity-induced cognitive impairment with semaglutide. This evidence concerns the gene HTT and obesity due to melanocortin 4 receptor deficiency.